Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by icecubeon Sep 07, 2015 2:31pm

57 Views

Post# 24083754

RE:RE:RE:RE:RE:RE:RE:Shame on the management

truthseeker2012 wrote: The CEO did earn his pay up until now. If no good drug deals are made as per his plan to justify what he has done, he should go as well, maybe to jali too.

I may not be impressed with the current work done by the executive of this company, but stating that the CEO should go to jail is a bit strong, don't you think?

This is, of course, on the assumption that you weren't meaning for the CEO to visit a West African poet.

Bullboard Posts

Hyundai partners with BlackBerry for next-gen digital cockpit platform